Abstract
BackgroundColorectal cancer remains a serious public health problem due to the poor prognosis. In the present study, we attempted to develop and validate a prognostic signature to predict the individual mortality risk in colorectal cancer patients.Materials and MethodsThe original study datasets were downloaded from The Cancer Genome Atlas database. The present study finally included 424 colorectal cancer patients with wholly gene expression information and overall survival information.ResultsA nine-lncRNA prognostic signature was built through univariate and multivariate Cox proportional regression model. Time-dependent receiver operating characteristic curves in model cohort demonstrated that the Harrell’s concordance indexes of nine-lncRNA prognostic signature were 0.768 (95% CI [0.717–0.819]), 0.778 (95% CI [0.727–0.829]) and 0.870 (95% CI [0.819–0.921]) for 1-year, 3-year and 5-year overall survival respectively. In validation cohort, the Harrell’s concordance indexes of nine-lncRNA prognostic signature were 0.761 (95% CI [0.710–0.812]), 0.801 (95% CI [0.750–0.852]) and 0.883 (95% CI [0.832–0.934]) for 1-year, 3-year and 5-year overall survival respectively. According to the median of nine-lncRNA prognostic signature score in model cohort, 424 CRC patients could be stratified into high risk group (n = 212) and low risk group (n = 212). Kaplan–Meier survival curves showed that the overall survival rate of high risk group was significantly lower than that of low risk group (P < 0.001).DiscussionThe present study developed and validated a nine-lncRNA prognostic signature for individual mortality risk assessment in colorectal cancer patients. This nine-lncRNA prognostic signature is helpful to evaluate the individual mortality risk and to improve the decision making of individualized treatments in colorectal cancer patients.
Highlights
Colorectal cancer (CRC) is one of the most common malignant tumors and one of the leading causes of cancer-related death, resulting in 135,430 estimated new cases and 50,260 estimated deaths in the United States in 2017 (Siegel et al, 2017; Siegel, Miller & Jemal, 2016)
Several studies constructed Long non-coding RNAs (lncRNAs)-based prognostic signatures to predict the overall survival of CRC patients by using Cox proportional regression model (Fan & Liu, 2018; Xing et al, 2018; Xue et al, 2017; Zeng et al, 2017)
There were 102 (24.0%) patients died during the follow-up period in model cohort, whereas there were 108 (25.5%) patients died during the follow-up period in validation cohort
Summary
Colorectal cancer (CRC) is one of the most common malignant tumors and one of the leading causes of cancer-related death, resulting in 135,430 estimated new cases and 50,260 estimated deaths in the United States in 2017 (Siegel et al, 2017; Siegel, Miller & Jemal, 2016). Several studies constructed lncRNAs-based prognostic signatures to predict the overall survival of CRC patients by using Cox proportional regression model (Fan & Liu, 2018; Xing et al, 2018; Xue et al, 2017; Zeng et al, 2017). These prognostic signatures have three limitations for clinical application. We attempted to develop and validate a prognostic signature to predict the individual mortality risk in colorectal cancer patients. The present study developed and validated a nine-lncRNA prognostic signature for individual mortality risk assessment in colorectal cancer patients. This nine-lncRNA prognostic signature is helpful to evaluate the individual mortality risk and to improve the decision making of individualized treatments in colorectal cancer patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
